Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07595549 | A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity | PHASE3 | NOT YET_RECRUITING | 954 | — | — | Jun 30, 2026 | Jun 21, 2028 | May 27, 2026 | - | — |
| NCT07400653 | A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | PHASE3 | RECRUITING | 999 | — | — | Feb 24, 2026 | May 16, 2028 | May 18, 2026 | 183 | United States, Argentina +9 |
| NCT07508241 | A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity | PHASE1 | RECRUITING | 20 | — | — | Mar 31, 2026 | Jan 27, 2027 | Apr 23, 2026 | 1 | United States |
To assess the effect of multiple SC doses of PF-08653944 on the plasma PK profile of acetaminophen, a marker for gastric emptying, in healthy adult participants with overweight or obesity.
To assess the effect of multiple SC doses of PF-08653944 on the plasma PK profile of acetaminophen, a marker for gastric emptying, in healthy adult participants with overweight or obesity.
| Arm | Type | Description |
|---|---|---|
| Treatment Arm 1 | EXPERIMENTAL | Participants will receive PF-08653944 by Subcutaneous Injection. |
| Treatment Arm 2 | EXPERIMENTAL | Participants will receive PF-08653944 by Subcutaneous Injection. |
| Treatment Arm 3 | EXPERIMENTAL | Participants will receive PF-08653944 by Subcutaneous Injection. |
| Treatment Arm 4 | EXPERIMENTAL | Participants will receive PF-08653944 by Subcutaneous Injection. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo by Subcutaneous Injection. |
| Period 1 | EXPERIMENTAL | Participants will receive a single oral dose of acetaminophen. |
| Period 2 | EXPERIMENTAL | Participants will receive SC dose of PF-08653944 and single oral dose of acetaminophen. |
| Period 3 | EXPERIMENTAL | Participants will receive SC dose of PF-0865394. |
| Period 4 | EXPERIMENTAL | Participants will receive SC dose of PF-0865394. |
| Period 5 | EXPERIMENTAL | Participants will receive SC dose of PF-08653944 and single oral dose of acetaminophen. |
| Period 6 | EXPERIMENTAL | Participants will receive single SC dose of PF-08653944 and single oral dose of acetaminophen. |
| Name | Type | Description |
|---|---|---|
| PF-08653944 | DRUG | By Subcutaneous Injection |
| Placebo | OTHER | By Subcutaneous Injection |
| Acetaminophen | DRUG | Oral suspension |
Inclusion Criteria: * Aged ≥18 years. * BMI of: ≥30 kg/m2 or ≥27.0 kg/m2 to \<30.0 kg/m2 and must have at least 1 of the following weight-related co-morbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2D. Exclusion Criteria: * Have a self-reported body we...